store at low temperature
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ginsenoside Rh3 is a natural product extracted from Ginseng C. A. Mey.Ginsenoside Rh3 has antifungal and antioxidant activities and induces Nrf2 activation in human retinal cells.
Description | Ginsenoside Rh3 is a natural product extracted from Ginseng C. A. Mey.Ginsenoside Rh3 has antifungal and antioxidant activities and induces Nrf2 activation in human retinal cells. |
In vitro | Ginsenoside Rh3 (0.01, 0.1, 1 and 10 μM) shows no cytotoxic effect at all concentrations.[2] Ginsenoside Rh3 treatment in retinal cells induces Nrf2 activation. The potential activity of Ginsenoside Rh3 is tested on Nrf2 signaling in the retinal pigment epithelium cells (RPEs). The qRT-PCR assay results demonstrate that treatment with Ginsenoside Rh3 dose-dependently increases mRNA transcription and expression of vital Nrf2-regulated genes, including HO1, NQO1, and GCLC. Consequently, protein expressions of these Nrf2-dependent genes (HO1, NQO1, and GCLC) are also significantly increased in Ginsenoside Rh3 (3-10 μM)-treated RPEs. Notably, although the Nrf2 mRNA level is unchanged after Ginsenoside Rh3 treatment, its protein level is significantly increased by Rh3[1]. EZ-Cytox assay is used to assess the effect of ginsenoside-Rh3 on SP 1-keratinocytes viability.[2] |
In vivo | Ginsenoside Rh3 (5 mg/kg; intravitreal injection; 30 min pre-treatment) significantly attenuates light-induced decrease of both a- and b-wave amplitude. The electroretinography (ERG)'s a-wave decreases to 46.03±1.62% % of the control level after light exposure, which is back to 71.84±7.51% with Ginsenoside Rh3 administration. The b-wave is 40.19±3.34% of the control level by light exposure, and Rh3 intravitreal injection brings back to 80.01±2.37% of the control level.[1] |
Cell Research | SP-1 keratinocytes are seeded in 96 well plates (2×10^4 cells/well). After 24 h, the media is replaced with media containing various concentrations of (A) SKRG, or (B) Ginsenoside Rh3 (0.01, 0.1, 1 and 10 μM). Control cells are treated with DMSO at a final concentration of 0.1%. After 24 h, the media containing the compounds or DMSO is replaced with media containing 10% EZ-Cytox. The cells are then incubated at 37°C for 1 h, and the absorbance is measured using a microplate reader at a wavelength of 450 nm. All assays are performed in triplicate [2]. |
Animal Research | The BALB/c mice (male, 5-6 week old, 17-18 g weight) are used. The pupillary dilation is performed before exposure to 5000 lx of white fluorescent light. Thirty min before light exposure, Ginsenoside Rh3 (at 5 mg/kg body weight) is injected intravitreally to the right eye. ERG recording after light exposure is also reported early. The b-wave amplitude is measured from the trough of the a-wave to the peak of the b-wave, and the amplitude of the a-wave is measured from the initial baseline [1]. |
Molecular Weight | 604.86 |
Formula | C36H60O7 |
CAS No. | 105558-26-7 |
store at low temperature
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ethanol: 25 mg/mL (41.33 mM)
DMSO: 3.02 mg/mL (5 mM), need ultrasonic and warming
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ginsenoside Rh3 105558-26-7 Immunology/Inflammation Microbiology/Virology oxidation-reduction Antioxidant Nrf2 Antifungal Ginsenoside Rh-3 Inhibitor inhibitor inhibit